LivaNova LIVN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
LivaNova (LIVN) Business Model and Operations Summary
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Key Insights
LivaNova (LIVN) Core Market Data and Business Metrics
Latest Closing Price
$39.03Market Cap
$2.12 BillionPrice-Earnings Ratio
33.65Total Outstanding Shares
54.35 Million SharesTotal Employees
2,900Dividend
No dividendIPO Date
February 10, 1993SIC Description
Electromedical & Electrotherapeutic ApparatusPrimary Exchange
NASDAQHeadquarters
20 Eastbourne Terrace, London, X0, W2 6LG
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $18.55 Million |
| Net Cash Flow | $145.68 Million |
| Net Cash Flow From Financing Activities | $18.55 Million |
| Net Cash Flow From Operating Activities | $183.04 Million |
| Net Cash Flow, Continuing | $153.43 Million |
| Net Cash Flow From Investing Activities | $-48.16 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Gross Profit | $870.87 Million |
| Income/Loss Before Equity Method Investments | $88.31 Million |
| Income Tax Expense/Benefit | $25.06 Million |
| Income Tax Expense/Benefit, Current | $18.26 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-52.29 Million |
| Other Comprehensive Income/Loss | $10.95 Million |
| Comprehensive Income/Loss | $10.95 Million |
| Comprehensive Income/Loss Attributable To Parent | $10.95 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $1.13 Billion |
| Other Current Liabilities | $322.40 Million |
| Inventory | $147.57 Million |
| Noncurrent Liabilities | $794.01 Million |
| Assets | $2.51 Billion |
| Other Non-current Assets | $971.65 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||